SRF Annual Report Update - Fluorochemicals To Support Growth In Chemicals In FY22: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Motilal Oswal Report .SRF Ltd.’s FY21 Annual Report highlights its performance and outlook across key businesses. Additionally, the company has announced its vision – Aspirations 2025, on the back of which it aims to achieve:professional reputation and value system, customer advocacy, innovation and technology leadership, and operational excellence. Here are the key highlights:The specialty chemicals business maintained its growth momentum during the year despite Covid-19 related disruptions impacted Q1 FY21. Specialty chemical business reported stellar revenue growth of 47% YoY to Rs 23.9 billion in FY21 despite achieving revenue growth of 56% in FY20. SRF remains focused on the agrochemicals and pharmaceuticals segments – wherein it collaborates with major global innovators on process development, commercialisation, and producing complex newage molecules with downstream applications..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

SRF Annual Report Update - Fluorochemicals To Support Growth In Chemicals In FY22: Motilal Oswal

SRF Annual Report Update - Fluorochemicals To Support Growth In Chemicals In FY22: Motilal Oswal

Choose a plan